OPKO Health (NASDAQ:OPK) Earns “Outperform” Rating from Barrington Research

Barrington Research reaffirmed their outperform rating on shares of OPKO Health (NASDAQ:OPK) in a research note issued to investors on Wednesday morning,Benzinga reports. They currently have a $2.25 target price on the biotechnology company’s stock.

A number of other brokerages have also commented on OPK. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Monday, March 3rd.

OPKO Health Price Performance

Shares of NASDAQ OPK opened at $1.74 on Wednesday. OPKO Health has a twelve month low of $0.86 and a twelve month high of $2.04. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30. The firm has a fifty day simple moving average of $1.61 and a 200 day simple moving average of $1.57. The company has a market capitalization of $1.17 billion, a PE ratio of -9.16 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.09. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. The business had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. On average, sell-side analysts forecast that OPKO Health will post -0.25 EPS for the current year.

Insider Buying and Selling

In other news, CEO Phillip Md Et Al Frost purchased 67,434 shares of the company’s stock in a transaction that occurred on Friday, February 28th. The shares were bought at an average cost of $1.71 per share, for a total transaction of $115,312.14. Following the completion of the transaction, the chief executive officer now directly owns 213,301,448 shares of the company’s stock, valued at $364,745,476.08. This trade represents a 0.03 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 764,971 shares of company stock worth $1,145,692 in the last ninety days. 47.26% of the stock is owned by insiders.

Institutional Investors Weigh In On OPKO Health

A number of institutional investors have recently modified their holdings of the stock. Intech Investment Management LLC bought a new stake in OPKO Health in the 3rd quarter worth about $190,000. Integrated Investment Consultants LLC bought a new position in shares of OPKO Health during the 3rd quarter valued at approximately $233,000. FMR LLC increased its stake in shares of OPKO Health by 103.6% in the third quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 11,089 shares in the last quarter. BNP Paribas Financial Markets increased its stake in OPKO Health by 736.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after buying an additional 217,450 shares in the last quarter. Finally, Rubric Capital Management LP grew its position in shares of OPKO Health by 9.6% during the third quarter. Rubric Capital Management LP now owns 48,706,640 shares of the biotechnology company’s stock worth $72,573,000 after purchasing an additional 4,284,336 shares in the last quarter. 64.63% of the stock is owned by hedge funds and other institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.